Navin Fluorine International's revenue for the latest quarter was Rs 5.18 billion, which is a 9.9% increase compared to the previous year but a 1% decline compared to the previous quarter.

The company's High-Performance Products (HPP) segment experienced a strong 23% year-on-year growth, driven by improved operations in HFO and R-32, as well as better pricing for R-22. The expansion of R-32 capacity is on track to be commissioned in February 2025, and the capital expenditure for AHF is expected to be completed by the end of FY25.

Despite a 15% decline in the specialty chemicals segment, management expects growth to rebound in the latter half of FY25 due to strong order visibility. The Contract Development and Manufacturing Organization (CDMO) vertical saw a 16% decline in revenue compared to the previous quarter, but a significant 42% increase compared to the previous year. The target is to achieve USD 100 million in revenue by FY27.

The stock is currently trading at 38 times the estimated FY27 earnings per share of Rs 87, with a target price set at Rs 3,523, reflecting a valuation of 45 times the FY26/FY27 EPS. Analysts maintain an 'Accumulate' rating on the stock.